Research ArticleOriginal Article
Open Access

Cytotoxicity anticancer activities of anastrozole against breast, liver hepatocellular, and prostate cancer cells

Firas Hassan, Gamal A. El-Hiti, Mays Abd-Allateef and Emad Yousif
Saudi Medical Journal April 2017, 38 (4) 359-365; DOI: https://doi.org/10.15537/smj.2017.4.17061

References

  1. ↵
    1. Yamamoto M,
    2. Hosoda M,
    3. Nakano K,
    4. Jia S,
    5. Hatanaka KC,
    6. Takakuwa E,
    7. et al.
    (2014) P53 accumulation is a strong predictor of recurrence in estrogen receptor-positive breast cancer patients treated with aromatase inhibitors. Cancer Sci 105:81–88.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Lauring L,
    2. Wolff AC
    (2016) Evolving role of the estrogen receptor as a predictive biomarker: ESR1 mutational status and endocrine resistance in breast cancer. J Clin Oncol 34:2950–2952.
    OpenUrlFREE Full Text
  3. ↵
    1. Bao T,
    2. Rudek MA
    (2011) The clinical pharmacology of anastrozole. Eur Oncol Haematol 7:106–108.
    OpenUrl
  4. ↵
    1. Miller WR,
    2. Larionov AA
    (2012) Understanding the mechanisms of aromatase inhibitor resistance. Breast Cancer Res 14:201.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Kümler I,
    2. Knoop AS,
    3. Jessing CAR,
    4. Ejlertsen B,
    5. Nielsen DL
    (2016) Review of hormone-based treatments in postmenopausal patients with advanced breast cancer focusing on aromatase inhibitors and fulvestrant. ESMO Open-Cancer Horizons 1:e000062.
    OpenUrl
  6. ↵
    1. Dahir M,
    2. Travers-Gustafson D
    (2014) Breast cancer, aromatase inhibitor therapy, and sexual functioning: a pilot study of the effects of vaginal testosterone therapy. Sex Med 2:8–15.
    OpenUrl
  7. ↵
    1. Das M,
    2. Manna K
    (2016) Chalcone scaffold in anticancer armamentarium: A molecular insight. J Toxicol, 7651047.
  8. ↵
    1. American Cancer Society
    (2011) Global Cancer Facts and Figures (American Cancer Society, USA, Atlanta (GA)), 2nd ed.
  9. ↵
    1. Alison MR
    (2011) Cancer, Encyclopedia of life sciences. Nature Publishing Group.
  10. ↵
    1. Peter ME
    (2011) Programmed cell death: apoptosis meets necrosis. Nature 471:310–312.
    OpenUrlCrossRefPubMedWeb of Science
  11. ↵
    1. Eaton SR,
    2. Mazuski JE
    (2013) Overview of severe clostridium difficile infection. Critical Care Clinics 29:827–839.
    OpenUrlCrossRefPubMed
  12. ↵
    1. Muthigi A,
    2. George AK,
    3. Brancato SJ,
    4. Agarwal PK
    (2016) Novel immunotherapeutic approaches to the treatment of urothelial carcinoma. Ther Adv Urol 8:203–214.
    OpenUrlCrossRef
  13. ↵
    1. Wellington KW
    (2015) Understanding cancer and the anticancer activities of naphthoquinones –a review. RSC Adv 5:20309–20338.
    OpenUrlCrossRef
  14. ↵
    1. Sabesan S,
    2. Olver I
    1. Skandarajah A
    (2014) in Principles of cancer surgery, Cancer Council Australia Oncology Education Committee, eds Sabesan S, Olver I (Cancer Council Australia, Sydney (Australia)).
  15. ↵
    1. Price P,
    2. Sikora K
    (2014) Treatment of Cancer (CRC Press, FL, USA), 6th ed.
  16. ↵
    1. Saraswathy M,
    2. Gong S
    (2013) Different strategies to overcome multidrug resistance in cancer. Biotechnol Adv 31:1397–1407.
    OpenUrlCrossRefPubMed
  17. ↵
    1. IRSA Radiation Therapy
    , Available form: http://www.irsa.org/radation_therapy.html. [Accessed 2016 September 1].
  18. ↵
    1. Abd-Allateef M,
    2. Hassan FA-A,
    3. Saleh WA
    (2016) J Al-Nahrain Univ, Study the effect of anastrozole on estradiol and aromatase enzyme in postmenopausal breast cancer patients, 19, pp 43–50.
    OpenUrl
  19. ↵
    1. Abdel-Megeed MF,
    2. Badr BE,
    3. Azaam MM,
    4. El-Hiti GA
    (2012) Synthesis, antimicrobial and anticancer activities of a novel series of diphenyl 1-(pyridin-3-yl)ethylphosphonates. Bioorg Med Chem 20:2252–2258.
    OpenUrlPubMed
  20. ↵
    1. Sweeney EE,
    2. McDaniel RE,
    3. Maximov PY,
    4. Fan P,
    5. Jordan VC
    (2012) Models and mechanisms of acquired antihormone resistance in breast cancer: significant clinical progress despite limitations. Horm Mol Biol Clin Investig 9:143–163.
    OpenUrlPubMed
  21. ↵
    1. Hole S,
    2. Pedersen A,
    3. Hasen S,
    4. Lundqvist J,
    5. Yde CW,
    6. Lykkesfeldt AE
    (2015) New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane. Int J Oncol 46:1481–1490.
    OpenUrlCrossRefPubMed
  22. ↵
    1. Duellman SJ,
    2. Zhou W,
    3. Meisenheimer P,
    4. Vidugiris G,
    5. Cali JJ,
    6. Gautam P,
    7. et al.
    (2015) Bioluminescent, Nonlytic, Real-Time Cell Viability Assay and Use in Inhibitor Screening. Assay Drug Dev Tech 13:456–465.
    OpenUrl
  23. ↵
    1. Hassan F,
    2. Abdul-Hameed A,
    3. Alshanon A,
    4. Abdullah MB,
    5. Huri HZ,
    6. et al.
    (2015) Antitumor activity for gold(III) complex by high content screening technique (HCS) and cell viability assay. Asian J Biochem 10:252–266.
    OpenUrl
  24. ↵
    1. Al-Jailawi MH,
    2. Nasir HM,
    3. Aziz GM
    (2015) Cytotoxic effect of biosurfactants produced by novel thermophillic Geobacillus thermoleovorans (JQ 912239). Int J Adv Res 3:632–637.
    OpenUrl
  25. ↵
    1. Ingle JN,
    2. Kalari KR,
    3. Buzdar AU,
    4. Robson ME,
    5. Goetz MP,
    6. Desta Z,
    7. et al.
    (2015) Estrogens and their precursors in postmenopausal women with early breast cancer receiving anastrozole. Steroids 99:32–83.
    OpenUrl
  26. ↵
    1. Topcul M,
    2. Cetin I,
    3. Ozlem KOM
    (2013) The effects of anastrozole on the proliferation of FM3A cells. J BUON 18:874–878.
    OpenUrl
  27. ↵
    1. Arimidex (Anastrozole) Tablet AstraZeneca Pharmaceuticals LP
    (2016) USA, Astrazeneca, Available from: https://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=5257.
  28. ↵
    1. Stoddart M
    (2011) J. Cell viability assays: introduction. Methods Mol Biol 740:1–6.
    OpenUrlCrossRefPubMed
  29. ↵
    1. In Riss TL,
    2. Moravec RA,
    3. Niles AL,
    4. Duellman S,
    5. Benink HA,
    6. Worzella TJ,
    7. et al.
    (2013) Assay Guidance Manual: Cell Viability Assays (Eli Lilly & Company and the National Center for Advancing Translational Sciences, Bethesda (MD)) Available from: https://www.ncbi.nlm.nih.gov/books/NBK53196/.
  30. ↵
    1. Dive C,
    2. Watson JV,
    3. Workman P
    (1990) Multiparametric analysis of cell membrane permeability by two colour flow cytometry with complementary fluorescent probes. Cytometry 11:244–252.
    OpenUrlCrossRefPubMed
  31. ↵
    1. Lopez-Novoa JM,
    2. Quiros Y,
    3. Vicente L,
    4. Morales AI,
    5. Lopez-Hernandez FJ
    (2011) New insights into the mechanism of aminoglycoside nephrotoxicity: an integrative point of view. Kidney Int 79:33–45.
    OpenUrlCrossRefPubMedWeb of Science
  32. ↵
    1. Wang Y-H,
    2. Xuan Z-H,
    3. Tian S,
    4. He G-R,
    5. Du G-H
    (2013) Myricitrin attenuates 6-hydroxydopamine-induced mitochondrial damage and apoptosis in PC12 cells via inhibition of mitochondrial oxidation. J Funct Foods 5:337–345.
    OpenUrl
  33. ↵
    1. Kim R,
    2. Emi M,
    3. Tanabe K
    (2006) Role of mitochondria as the gardens of cell death. Cancer Chemother Pharmacol 57:545–553.
    OpenUrlCrossRefPubMedWeb of Science
  34. ↵
    1. Kilbride SM,
    2. Prehn JHM
    (2013) Central roles of apoptotic proteins in mitochondrial function. Oncogene 32:2703–2711.
    OpenUrlCrossRefPubMedWeb of Science
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section